📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. (2021)

First Author: Ali Z

Attributed to: MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1080/1744666x.2021.1967748

PubMed Identifier: 34384327

Publication URI: http://europepmc.org/abstract/MED/34384327

Type: Journal Article/Review

Volume: 17

Parent Publication: Expert review of clinical immunology

Issue: 10

ISSN: 1744-666X